Abstracts tagged "MALT lymphoma"

Abstract Number: 2432 • 2019 ACR/ARP Annual Meeting
Thymic Stromal Lymphopoietin (TSLP) as a Biomarker of Primary Sjögren’s Syndrome (pSS) and Related Lymphoma: Results in Independent Cohorts
Saviana Gandolfo¹, Cinzia Fabro ¹, Serena Colafrancesco ², Francesco Carubbi ³, Francesco Ferro ⁴, Elena Bartoloni ⁵, Efstathia Kapsogeorgou ⁶, Andreas Goules ⁶, Luca Quartuccio ¹, Roberta Priori ², Alessia Alunno ⁵, Guido Valesini ², Roberto Giacomelli ³, Roberto Gerli ⁵, Chiara Baldini ⁴, Athanasios Tzioufas ⁶ and Salvatore De Vita ¹, ¹Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ²Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, Roma, Italy, ³Rheumatology Unit, Department of Biotechnological and Applied Clinical Science, School of Medicine, University of L'Aquila, L'Aquila, Italy, L'Aquila, Italy, ⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, ⁵Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, ⁶Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece
Background/Purpose: Thymic stromal lymphopoietin (TSLP) has been implicated in primary Sjögren’s syndrome (pSS) and related B-cell lymphoproliferation / lymphoma (NHL) by tissue studies on salivary…
Abstract Number: 2433 • 2019 ACR/ARP Annual Meeting
Fatigue in Primary Sjögren’s Syndrome as a Manifestation of Heavier Disease Activity of Mucosa-Associated Lymphoid Tissue (MALT)
Saviana Gandolfo¹, Marco Binutti ¹, Elena Doriguzzi Breatta ¹, Cinzia Fabro ¹ and Salvatore De Vita ¹, ¹Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy
Background/Purpose: Fatigue is one of the most prevalent and impacting symptoms in primary Sjögren’s syndrome (pSS), significantly impairing the patient quality of life. To date,…
Abstract Number: 2436 • 2019 ACR/ARP Annual Meeting
The Salivary Glands as the Key Site of Inflammation and Lymphoproliferation Leading to Lymphoma in Primary Sjögren’s Syndrome: Relevance for Dedicated Scoring, Biomarker Development and Lymphoma Prevention
Salvatore De Vita¹, Saviana Gandolfo ¹, Chiara Baldini ², Miriam Isola ³, Michael Voulgarelis ⁴, Andreas Goules ⁴, Ginevra De Marchi ⁵, Marco Binutti ¹, Sara Zandonella Callegher ⁵, Francesco Ferro ², Claudio Battistella ³, Loukas Chatzis ⁴ and Athanasios Tzioufas ⁴, ¹Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ²Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, ³Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ⁴Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁵Rheumatology Clinic, Udine University Hospital, Udine, Italy, Udine, Italy
Background/Purpose: Since the risk of B-cell non-Hodgkin’s lymphoma (NHL) evolution is increased in primary Sjögren’s syndrome (pSS), its prevention represents a relevant therapeutic end-point. A…
Abstract Number: 637 • 2015 ACR/ARHP Annual Meeting
Repeated B Lymphocyte Depletion Therapy with Rituximab in Sjögren’s Syndrome: A Single Center Experience
Francesco Ferro¹, Chiara Baldini¹, Nicoletta Luciano¹, Maurizio Mazzantini¹, Daniela Martini¹, Sara Galimberti², Valentina Donati³, Marta Mosca⁴ and Stefano Bombardieri¹, ¹Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ²Hematology Unit, University of Pisa, Italy, Pisa, Italy, ³Department of Pathology, AOUP, Pisa, Italy, Pisa, Italy, ⁴University of Pisa, Pisa, Italy
Background/Purpose: Recent insights from open studies and randomized clinical trials have shown the effectiveness of Rituximab (RTX) in controlling disease activity, patients’ subjective symptoms and…
Abstract Number: 644 • 2015 ACR/ARHP Annual Meeting
Predicting the Risk for Lymphoma Development in Sjögren’s Syndrome: An Easy to Use Clinical Tool
Sofia Fragkioudaki¹, Clio Mavragani² and Haralampos M. Moutsopoulos³, ¹Physiology, Medical School of Athens, Department of Physiology, Athens, Greece, ²Physiology, Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, ³Department of Pathophysiology, Medical School of Athens, Department of Pathophysiology, Athens, Greece
Background/Purpose: Studies from our and other laboratories have shown that clinical, laboratory and serological features at the first evaluation of a patient with primary Sjogren’s…
Abstract Number: 2791 • 2015 ACR/ARHP Annual Meeting
TREX-1 Variants in Sjögren’s Syndrome Related Lymphomagenesis
Panagiota Makri¹, Adrianos Nezos², Michael Voulgarelis³, Haralampos M. Moutsopoulos⁴ and Clio Mavragani⁵, ¹Physiology, Department of Physiology, School of Medicine, University of Athens, Athens, Greece, ²Physiology, Department of Experimental Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, ³Pathophysiology, Department of Pathophysiology, Medical School of Athens, Athens, Greece, ⁴Department of Pathophysiology, Medical School of Athens, Department of Pathophysiology, Athens, Greece, ⁵Physiology, Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Three prime Repair Exonuclease 1 (TREX-1) is an exonuclease involved in DNA repair preventing genomic instability. TREX-1 variants have been previously associated with activation of type…
Abstract Number: 3075 • 2015 ACR/ARHP Annual Meeting
Salivary Gland FcRL4+ B-Cells Are a Potential Source of Progenitor Cells for MALT Lymphoma in Primary Sjögren’s Syndrome
Erlin A. Haacke¹, Frans G.M. Kroese², Philip Kluin³, Petra M. Meiners⁴, Annie Visser⁵, Fred K.L. Spijkervet⁶ and Hendrika Bootsma⁷, ¹Pathology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Department of Pathology and Medical Biology, UMCG Groningen, Groningen, Netherlands, ⁴Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵Rheumatology and Clinical Immunology, UMC Groningen, Groningen, Netherlands, ⁶Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, Netherlands, ⁷Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: Patients with primary Sjögren's Syndrome (pSS) have an increased risk of non-Hodgkin's lymphoma, predominantly of the Mucosa Associated Lymphoid Tissue (MALT) type, which commonly…
Abstract Number: 2538 • 2014 ACR/ARHP Annual Meeting
Ultrasound-Guided Core Needle Biopsy of the Major Salivary Glands Is a Safe and Useful Diagnostic Tool in the Evaluation of Suspected or Established Sjögren’s Syndrome
Anand Narayan¹, Thomas Grader-Beck², Julius Birnbaum³, Jean Kim⁴, Qing Kay Li⁵, Deborah Belchis⁵, Joel Fradin¹ and Alan N. Baer⁶, ¹Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Ultrasound-guided core needle biopsy (CNB) has greater inherent risks than fine-needle aspiration for the diagnosis of major salivary gland neoplasms, but provides tissue for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].